Brokerages forecast that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will announce earnings of ($0.32) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with estimates ranging from ($0.58) to ($0.12). Dicerna Pharmaceuticals posted earnings per share of ($0.28) in the same quarter last year, which would suggest a negative year over year growth rate of 14.3%. The company is expected to announce its next quarterly earnings report on Wednesday, August 14th.
Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.16). Dicerna Pharmaceuticals had a negative return on equity of 52.17% and a negative net margin of 1,284.93%. The firm had revenue of $3.11 million for the quarter, compared to analysts’ expectations of $10.59 million.
DRNA opened at $11.83 on Friday. Dicerna Pharmaceuticals has a fifty-two week low of $9.31 and a fifty-two week high of $17.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The stock has a market cap of $812.37 million, a PE ratio of -9.86 and a beta of 2.30.
In other news, insider James B. Weissman sold 15,000 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $15.00, for a total transaction of $225,000.00. Following the transaction, the insider now owns 39,480 shares of the company’s stock, valued at approximately $592,200. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 19.85% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Candriam Luxembourg S.C.A. increased its holdings in shares of Dicerna Pharmaceuticals by 53.5% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 447,500 shares of the biopharmaceutical company’s stock valued at $4,784,000 after acquiring an additional 156,000 shares during the last quarter. Federated Investors Inc. PA increased its holdings in shares of Dicerna Pharmaceuticals by 61,484.1% during the 3rd quarter. Federated Investors Inc. PA now owns 252,495 shares of the biopharmaceutical company’s stock valued at $3,853,000 after acquiring an additional 252,085 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Dicerna Pharmaceuticals by 46.0% during the 4th quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock valued at $46,300,000 after acquiring an additional 1,364,155 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Dicerna Pharmaceuticals by 15.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 185,441 shares of the biopharmaceutical company’s stock valued at $2,830,000 after buying an additional 24,543 shares during the last quarter. Finally, Emory University acquired a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at approximately $1,844,000. 89.65% of the stock is currently owned by institutional investors and hedge funds.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Read More: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.